GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (STU:HXB2) » Definitions » Price-to-Free-Cash-Flow

AIM ImmunoTech (STU:HXB2) Price-to-Free-Cash-Flow : N/A (As of May. 24, 2024)


View and export this data going back to . Start your Free Trial

What is AIM ImmunoTech Price-to-Free-Cash-Flow?

As of today (2024-05-24), AIM ImmunoTech's share price is €0.354. AIM ImmunoTech's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.42. Hence, AIM ImmunoTech's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for AIM ImmunoTech's Price-to-Free-Cash-Flow or its related term are showing as below:

STU:HXB2's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.68
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

AIM ImmunoTech's Free Cash Flow per Share for the three months ended in Mar. 2024 was €-0.09. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was €-0.42.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -9.40% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 46.70% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 45.60% per year.

During the past 13 years, AIM ImmunoTech's highest 3-Year average Free Cash Flow per Share Growth Rate was 69.60% per year. The lowest was -33.70% per year. And the median was 10.30% per year.


AIM ImmunoTech Price-to-Free-Cash-Flow Historical Data

The historical data trend for AIM ImmunoTech's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Price-to-Free-Cash-Flow Chart

AIM ImmunoTech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AIM ImmunoTech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AIM ImmunoTech's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, AIM ImmunoTech's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AIM ImmunoTech's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Price-to-Free-Cash-Flow falls into.



AIM ImmunoTech Price-to-Free-Cash-Flow Calculation

AIM ImmunoTech's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.354/-0.424
=N/A

AIM ImmunoTech's Share Price of today is €0.354.
AIM ImmunoTech's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.42.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

AIM ImmunoTech  (STU:HXB2) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


AIM ImmunoTech Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


AIM ImmunoTech (STU:HXB2) Business Description

Traded in Other Exchanges
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech (STU:HXB2) Headlines

No Headlines